Diabetic macular edema (DME) is an eye condition that can lead to vision loss in people with diabetes. It occurs as a result of diabetic retinopathy — damaged blood vessels in the eyes due to elevated ...

Diabetic retinopathy in patients with DME is the fourth approved indication for EYLEA in the U.S. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Credit: Regeneron. Eylea HD is supplied as a sterile, aqueous solution for intravitreal injection in a single-dose vial containing 8mg of aflibercept. The Food and Drug Administration (FDA) has ...

Diabetic retinopathy (DR) and diabetic macular edema (DME) are two common vision conditions related to diabetes. While both can lead to vision loss, they are different eye conditions. DR is a ...

Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer ...

Many people with diabetes have the earliest stage of diabetic retinopathy, called mild nonproliferative diabetic retinopathy (NPDR), without even knowing it, according to the American Academy of ...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are indicated ...

The most common cause of vision loss in people with diabetes, diabetic retinopathy is the leading cause of blindness among adults aged 20 to 74 1 and affects nearly 7.7 million people in the U.S. 2 ...

A four-year clinical study has found that while early treatment of diabetes-related eye disease using anti-vascular endothelial growth factor (anti-VEGF; aflibercept) slowed progression to severe ...